<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01242241</url>
  </required_header>
  <id_info>
    <org_study_id>H-22091</org_study_id>
    <nct_id>NCT01242241</nct_id>
  </id_info>
  <brief_title>Propofol in Obese Children</brief_title>
  <official_title>Propofol in Obese Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Baylor College of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Obesity in children,as in adults,has rapidly become a public health concern. Studies in&#xD;
      adults have shown that obesity, now considered to be a disease state, is a modifier of the&#xD;
      effect of drugs on the body as well as how the body handles the drug.The anesthetic&#xD;
      management of obese children poses a variety of significant challenges which include&#xD;
      determination of the appropriate dose of anesthetic intravenous agents. Dosing of most drugs&#xD;
      is calculated based on the effective dose in 50% of patients but the more practical and&#xD;
      required information is the effective dose in 95%(ED95%)of patients. The aim of this study is&#xD;
      to determine the effective dose in 95% of patients(children). The hypothesis is the ED95 of&#xD;
      propofol in obese children will be higher than that of non-obese children.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All subjects were fasted in keeping with our institutional NPO guidelines and had IV access&#xD;
      established in the upper extremity in the pre-anesthesia area. No pre-induction sedative&#xD;
      drugs were administered. Routine ASA monitors were applied and in cooperative children, a&#xD;
      bispectral index (BIS) monitor pad (Aspect Medical Systems, Inc., Shattuck, MA) was applied&#xD;
      over the forehead. Each child was given a water-filled syringe to hold tightly in the hand&#xD;
      contralateral to the IV site. Lidocaine 1 mg/kg IV (maximum of 60 mg) was administered to&#xD;
      decrease pain with propofol injection. A predetermined sequential dose of propofol (Diprivan,&#xD;
      APP Pharmaceuticals, LLC, Schaumburg, IL) was administered IV rapidly over 10 seconds,&#xD;
      followed by a normal saline flush.&#xD;
&#xD;
      Biased Coin Design An independent observer blinded to the propofol dose tested for lash&#xD;
      reflex at 20 seconds, and also recorded the vital signs; level of sedation, using the&#xD;
      University of Michigan sedation scale (UMSS)10; and the BIS values at 20, 60, and 120 seconds&#xD;
      after propofol administration, along with the time the patient dropped the handheld syringe.&#xD;
      The study was terminated after 120 seconds and additional propofol administered if needed.&#xD;
&#xD;
      Both nonobese and obese patients were studied in parallel using the biased coin design (BCD),&#xD;
      in which a certain number of dose levels (k levels) are chosen with a fixed constant&#xD;
      interval. In the absence of dose-ranging data in obese children, we chose a low starting dose&#xD;
      of 1.0 mg/kg for the first patient in both groups to avoid missing a desired response in this&#xD;
      patient population. If the desired effect (loss of lash reflex at 20 seconds) was not&#xD;
      observed, the next patient in the assigned group received the next higher dose of propofol in&#xD;
      predetermined increments (0.25 mg/kg) from the previous dose. If the desired effect was&#xD;
      observed, the next patient in the same assigned group was randomized with a 0.95 probability&#xD;
      to receive the same dose or a 0.05 probability to receive the next lower dose (also in 0.25&#xD;
      mg/kg decrements).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2008</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose of Propofol That Caused Loss of Consciousness in 95% (ED95) of Obese and Non-obese Children</measure>
    <time_frame>20 seconds</time_frame>
    <description>Propofol is administered over 10 seconds. 20 seconds after adminstration, loss of consciousness is assessed by the presence or absence of a lash reflex. The dose responsible for loss of lash reflex/consciousness in 95% of patients was determined in mg/kg.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Depth of Sedation</measure>
    <time_frame>30 seconds, 1 minute, and 2 minutes</time_frame>
    <description>After propofol administration, the patient was assessed for depth of sedation at 30 seconds, 1 minute, and 2 minutes using the University of Michigan Sedation Scale (UMSS) and Ramsay Sedation Scale. UMSS assesses the level of alertness on a five-point scale ranging from 1 (wide awake) to 5 (unarousable with deep stimulation). Ramsay Sedation Scale assesses the level of sedation on a six-point scale ranging from 1 (Patient is anxious and agitated or restless, or both) to 6 (Patient exhibits no response).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Pharmacodynamics</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Non-obese</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Non-obese children categorized as those with a body mass index(BMI)between 25-84th percentile</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Obese children</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Obese children are categorized as those with a body mass index &gt;95th percentile</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>Each Obese child/subject in this group will receive a predetermined dose of propofol ranging from 1.0mg/kg to 4.25mg/kg to induce loss of consciousness depending on the response (presence or absence of lash reflex) of the preceding patient to his/her assigned dose (biased coin design)</description>
    <arm_group_label>Obese children</arm_group_label>
    <other_name>Diprivan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>This arm of patients(non-obese)will act as the control group for the obese children. Each non-obese child/subject will receive a predetermined dose of propofol from a range of 1.0mg/kg to 4.25mg/kg depending on the response of the previous patient to their assigned dose( biased coin design)</description>
    <arm_group_label>Non-obese</arm_group_label>
    <other_name>Diprivan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Children between the ages of 3 and 17 years who fall into the categories of&#xD;
             non-obese(BMI percentile between 25-84th percentile) or obese(&gt;95th percentile)&#xD;
&#xD;
          2. American Society of Anesthesiology(ASA) classification 1 or 2-&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients classified as ASA (American Society of Anesthesiology) Class 3 or greater.&#xD;
&#xD;
          2. Patients with documented kidney or liver disease or those presenting for open surgery&#xD;
             on the liver or kidney.&#xD;
&#xD;
          3. Patients who will NOT be receiving propofol for induction as part of their anesthetic&#xD;
             regimen.&#xD;
&#xD;
          4. Patients who are currently on anti-convulsant medication or receiving drugs with&#xD;
             sedative effects.&#xD;
&#xD;
          5. Patients currently being treated for attention deficit disorder.&#xD;
&#xD;
          6. Patients who are diagnosed with failure to thrive or those with a BMI less than 25th&#xD;
             percentile.&#xD;
&#xD;
          7. Patients who are hemodynamically unstable.&#xD;
&#xD;
          8. Patients with egg allergy.&#xD;
&#xD;
          9. Patients with low levels of albumin -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olutoyin A Olutoye, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Texas Children's Hospital, Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Pace NL, Stylianou MP. Advances in and limitations of up-and-down methodology: a pr√©cis of clinical use, study design, and dose estimation in anesthesia research. Anesthesiology. 2007 Jul;107(1):144-52. Review.</citation>
    <PMID>17585226</PMID>
  </reference>
  <reference>
    <citation>Mulla H, Johnson TN. Dosing dilemmas in obese children. Arch Dis Child Educ Pract Ed. 2010 Aug;95(4):112-7. doi: 10.1136/adc.2009.163055. Epub 2010 Jun 28. Review.</citation>
    <PMID>20585055</PMID>
  </reference>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>November 15, 2010</study_first_submitted>
  <study_first_submitted_qc>November 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2010</study_first_posted>
  <results_first_submitted>January 26, 2015</results_first_submitted>
  <results_first_submitted_qc>December 18, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 21, 2020</results_first_posted>
  <last_update_submitted>December 18, 2020</last_update_submitted>
  <last_update_submitted_qc>December 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Baylor College of Medicine</investigator_affiliation>
    <investigator_full_name>Olutoyin A. Olutoye</investigator_full_name>
    <investigator_title>Associate Professorof Anesthesiology &amp; Pediatrics</investigator_title>
  </responsible_party>
  <keyword>Propofol</keyword>
  <keyword>Childhood obesity</keyword>
  <keyword>Pharmacodynamics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 12, 2012</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/41/NCT01242241/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were recruited in the operating room setting between the period of April 2008 to December 2011</recruitment_details>
      <pre_assignment_details>A total of 213 patients were screened for study eligibility. Eighty-two patients were excluded; 51 did not meet inclusion criteria either becasue they declined participation, did not have intravenous access, were re-scheduled due to inadequate preparation for surgery or patient illness. All patients enrolled completed the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Obese Children</title>
          <description>Obese children are categorized as those with a body mass index &gt;95th percentile&#xD;
Propofol : Each Obese child/subject in this group received a predetermined dose of propofol ranging from 1.0mg/kg to 4.25mg/kg to induce loss of consciousness depending on the response (presence or absence of lash reflex) of the preceding patient to his/her assigned dose (biased coin design)</description>
        </group>
        <group group_id="P2">
          <title>Non-obese</title>
          <description>Non-obese children categorized as those with a body mass index(BMI)between 25-84th percentile&#xD;
Propofol : This arm of patients(non-obese)served as the control group for the obese children. Each non-obese child/subject received a predetermined dose of propofol from a range of 1.0mg/kg to 4.25mg/kg depending on the response of the previous patient to their assigned dose( biased coin design)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Obese Children</title>
          <description>Obese children are categorized as those with a body mass index &gt;95th percentile&#xD;
Propofol : Each Obese child/subject in this group received a predetermined dose of propofol ranging from 1.0mg/kg to 4.25mg/kg to induce loss of consciousness depending on the response (presence or absence of lash reflex) of the preceding patient to his/her assigned dose (biased coin design)</description>
        </group>
        <group group_id="B2">
          <title>Non-obese</title>
          <description>Non-obese children categorized as those with a body mass index(BMI)between 25-84th percentile&#xD;
Propofol : This arm of patients(non-obese)served as the control group for the obese children. Each non-obese child/subject received a predetermined dose of propofol from a range of 1.0mg/kg to 4.25mg/kg depending on the response of the previous patient to their assigned dose( biased coin design)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="40"/>
            <count group_id="B3" value="80"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.69" spread="2.89"/>
                    <measurement group_id="B2" value="12.70" spread="3.90"/>
                    <measurement group_id="B3" value="12.69" spread="3.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.29" spread="5.12"/>
                    <measurement group_id="B2" value="19.01" spread="2.60"/>
                    <measurement group_id="B3" value="24.65" spread="6.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Dose of Propofol That Caused Loss of Consciousness in 95% (ED95) of Obese and Non-obese Children</title>
        <description>Propofol is administered over 10 seconds. 20 seconds after adminstration, loss of consciousness is assessed by the presence or absence of a lash reflex. The dose responsible for loss of lash reflex/consciousness in 95% of patients was determined in mg/kg.</description>
        <time_frame>20 seconds</time_frame>
        <population>The sample size of 40 patients in each group was based on previous simulation studies which used the biased coin design in which a group size of 20-40 patients was shown to demonstrate stable estimates of the target dose for most scenarios.</population>
        <group_list>
          <group group_id="O1">
            <title>Obese Children</title>
            <description>Obese children are categorized as those with a body mass index &gt;95th percentile&#xD;
Propofol : Each Obese child/subject in this group received a predetermined dose of propofol ranging from 1.0mg/kg to 4.25mg/kg to induce loss of consciousness depending on the response (presence or absence of lash reflex) of the preceding patient to his/her assigned dose (biased coin design)</description>
          </group>
          <group group_id="O2">
            <title>Non-obese</title>
            <description>Non-obese children categorized as those with a body mass index(BMI)between 25-84th percentile&#xD;
Propofol : This arm of patients(non-obese)served as the control group for the obese children. Each non-obese child/subject received a predetermined dose of propofol from a range of 1.0mg/kg to 4.25mg/kg depending on the response of the previous patient to their assigned dose( biased coin design)</description>
          </group>
        </group_list>
        <measure>
          <title>Dose of Propofol That Caused Loss of Consciousness in 95% (ED95) of Obese and Non-obese Children</title>
          <description>Propofol is administered over 10 seconds. 20 seconds after adminstration, loss of consciousness is assessed by the presence or absence of a lash reflex. The dose responsible for loss of lash reflex/consciousness in 95% of patients was determined in mg/kg.</description>
          <population>The sample size of 40 patients in each group was based on previous simulation studies which used the biased coin design in which a group size of 20-40 patients was shown to demonstrate stable estimates of the target dose for most scenarios.</population>
          <units>mg/kg</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="1" upper_limit="2.25"/>
                    <measurement group_id="O2" value="2.125" lower_limit="1" upper_limit="3.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Depth of Sedation</title>
        <description>After propofol administration, the patient was assessed for depth of sedation at 30 seconds, 1 minute, and 2 minutes using the University of Michigan Sedation Scale (UMSS) and Ramsay Sedation Scale. UMSS assesses the level of alertness on a five-point scale ranging from 1 (wide awake) to 5 (unarousable with deep stimulation). Ramsay Sedation Scale assesses the level of sedation on a six-point scale ranging from 1 (Patient is anxious and agitated or restless, or both) to 6 (Patient exhibits no response).</description>
        <time_frame>30 seconds, 1 minute, and 2 minutes</time_frame>
        <population>Due to unavoidable circumstances during a clinical surgery, depth of sedation was not able to be collected on every subject at every time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Obese Children</title>
            <description>Obese children are categorized as those with a body mass index &gt;95th percentile&#xD;
Propofol : Each Obese child/subject in this group received a predetermined dose of propofol ranging from 1.0mg/kg to 4.25mg/kg to induce loss of consciousness depending on the response (presence or absence of lash reflex) of the preceding patient to his/her assigned dose (biased coin design)</description>
          </group>
          <group group_id="O2">
            <title>Non-obese</title>
            <description>Non-obese children categorized as those with a body mass index(BMI)between 25-84th percentile&#xD;
Propofol : This arm of patients(non-obese)served as the control group for the obese children. Each non-obese child/subject received a predetermined dose of propofol from a range of 1.0mg/kg to 4.25mg/kg depending on the response of the previous patient to their assigned dose( biased coin design)</description>
          </group>
        </group_list>
        <measure>
          <title>Depth of Sedation</title>
          <description>After propofol administration, the patient was assessed for depth of sedation at 30 seconds, 1 minute, and 2 minutes using the University of Michigan Sedation Scale (UMSS) and Ramsay Sedation Scale. UMSS assesses the level of alertness on a five-point scale ranging from 1 (wide awake) to 5 (unarousable with deep stimulation). Ramsay Sedation Scale assesses the level of sedation on a six-point scale ranging from 1 (Patient is anxious and agitated or restless, or both) to 6 (Patient exhibits no response).</description>
          <population>Due to unavoidable circumstances during a clinical surgery, depth of sedation was not able to be collected on every subject at every time point.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>UMSS - 30 seconds</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.65" lower_limit="1" upper_limit="4"/>
                    <measurement group_id="O2" value="3.57" lower_limit="1" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UMSS - 1 minute</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.86" lower_limit="1" upper_limit="4"/>
                    <measurement group_id="O2" value="3.73" lower_limit="1" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UMSS - 2 minutes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.82" lower_limit="1" upper_limit="4"/>
                    <measurement group_id="O2" value="3.67" lower_limit="1" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ramsay - 30 seconds</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.74" lower_limit="2" upper_limit="6"/>
                    <measurement group_id="O2" value="5.71" lower_limit="1" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ramsay - 1 minute</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.92" lower_limit="4" upper_limit="6"/>
                    <measurement group_id="O2" value="5.83" lower_limit="2" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ramsay - 2 minutes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.92" lower_limit="4" upper_limit="6"/>
                    <measurement group_id="O2" value="5.86" lower_limit="2" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From 0-120 seconds of propofol administration</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Non-obese</title>
          <description>Non-obese children categorized as those with a body mass index(BMI)between 25-84th percentile&#xD;
Propofol: This arm of patients(non-obese)will act as the control group for the obese children. Each non-obese child/subject will receive a predetermined dose of propofol from a range of 1.0mg/kg to 4.25mg/kg depending on the response of the previous patient to their assigned dose( biased coin design)</description>
        </group>
        <group group_id="E2">
          <title>Obese Children</title>
          <description>Obese children are categorized as those with a body mass index &gt;95th percentile&#xD;
Propofol: Each Obese child/subject in this group will receive a predetermined dose of propofol ranging from 1.0mg/kg to 4.25mg/kg to induce loss of consciousness depending on the response (presence or absence of lash reflex) of the preceding patient to his/her assigned dose (biased coin design)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Olutoyin A. Olutoye</name_or_title>
      <organization>Baylor College of Medicine</organization>
      <phone>832-824-5800</phone>
      <email>oao@bcm.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

